Site Editor

Sandy Srinivas, MD


Alan H. Bryce, MD, on Clinical Implications of Findings on Rucaparib, Docetaxel, and Androgen Pathway Inhibitor Therapy for Prostate Cancer

Posted: Wednesday, March 8, 2023

Alan H. Bryce, MD, of the Mayo Clinic, discusses clinical issues related to new findings from the TRITON3 study on the use of PARP inhibitors to treat patients with chemotherapy-naive metastatic castration-resistant prostate cancer harboring delterious alterations of BRCA1, BRCA2, or ATM. The data showed that rucaparib improved radiographic progression-free survival compared with either docetaxel or abiraterone and enzalutamide in disease with BRCA1 or BRCA2 alterations.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.